CRL - Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending Narrows Outlook | Benzinga
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the consensus of $1 billion.
The company reported adjusted EPS of $2.72, beating the Wall Street estimate of $2.37.
Acquisitions contributed 0.2% to consolidated third-quarter revenue growth. The impact of foreign currency translation benefited reported revenue growth by 1.4%. The divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 1.9%.
Excluding the ...